Analyses of EFS From Start of Treatment
Variable . | Median EFS5-150 (95% CI) . | Univariate P Value5-151 . | Multivariate P Value . | Comment . |
---|---|---|---|---|
inv16 or t(8; 21) | None [65, −] | .003 | .029 | Unfavorable effect complex −5, −7 increases with time |
Complex −5, −7 | 10 [8, 15] | <.001 | <.001 | |
Other abnormal or IM | 24 [17, 32] | <.001 | .002 | |
Normal karyotype | 46 [30, 76] | <.001 | — | |
PS ≤ 2 | 31 [27, 37] | <.001 | <.001 | Unfavorable effect PS > 2 levels off by 12 weeks |
PS > 2 | 4 [2, 10] | — | ||
LAFR | 31 [27, 41] | <.001 | .003 | LAFR favorable only for initial 8 weeks |
No LAFR | 17 [11, 24] | — | ||
IA | 52 [37, 81] | .003 | — | Unfavorable effect F + A disappears by 32 weeks |
IA + G | 57 [33, 76] | <.001 | NS | |
F + A | 12 [10, 28] | .015 | .05 | |
FLAG | 23 [15, 31] | .24 | NS | |
FLAG + Ida | 14.5 [12, 21] | <.001 | NS | |
RAEB | 18 [13, 26] | .047 | NS | |
RAEB-t | 30 [21, 46] | .59 | NS (.081) | |
AML | 29 [22, 35] | .48 | — | |
Age | Decreases with increasing age | <.001 | .001 | Unfavorable effect increasing age disappears by 40 wk from start of treatment |
AHD | Decreases with length of AHD up to plateau at AHD of 10-20 mo | <.001 | <.001 |
Variable . | Median EFS5-150 (95% CI) . | Univariate P Value5-151 . | Multivariate P Value . | Comment . |
---|---|---|---|---|
inv16 or t(8; 21) | None [65, −] | .003 | .029 | Unfavorable effect complex −5, −7 increases with time |
Complex −5, −7 | 10 [8, 15] | <.001 | <.001 | |
Other abnormal or IM | 24 [17, 32] | <.001 | .002 | |
Normal karyotype | 46 [30, 76] | <.001 | — | |
PS ≤ 2 | 31 [27, 37] | <.001 | <.001 | Unfavorable effect PS > 2 levels off by 12 weeks |
PS > 2 | 4 [2, 10] | — | ||
LAFR | 31 [27, 41] | <.001 | .003 | LAFR favorable only for initial 8 weeks |
No LAFR | 17 [11, 24] | — | ||
IA | 52 [37, 81] | .003 | — | Unfavorable effect F + A disappears by 32 weeks |
IA + G | 57 [33, 76] | <.001 | NS | |
F + A | 12 [10, 28] | .015 | .05 | |
FLAG | 23 [15, 31] | .24 | NS | |
FLAG + Ida | 14.5 [12, 21] | <.001 | NS | |
RAEB | 18 [13, 26] | .047 | NS | |
RAEB-t | 30 [21, 46] | .59 | NS (.081) | |
AML | 29 [22, 35] | .48 | — | |
Age | Decreases with increasing age | <.001 | .001 | Unfavorable effect increasing age disappears by 40 wk from start of treatment |
AHD | Decreases with length of AHD up to plateau at AHD of 10-20 mo | <.001 | <.001 |